The risk of hypertension related to anti-VEGF therapy is also higher in patients with metastatic RCC compared to other indications as reported in sorafenib (17% and 5% of RCC [33] and hepatocellular carcinoma [34] treated patients the same dose of sorafenib, resp). Here, VEGFA is linked to hypertensive disorder.